Switching from originator biological agents to biosimilars: what is the evidence and what are the issues?

about

P2860

Q50108062-7B052184-6CD3-4123-988E-C38802E90671

P2860

Switching from originator biological agents to biosimilars: what is the evidence and what are the issues?

Item

http://www.wikidata.org/entity/Q42360803

description

2017 nî lūn-bûn

@nan

2017年の論文

@ja

2017年論文

@yue

2017年論文

@zh-hant

2017年論文

@zh-hk

2017年論文

@zh-mo

2017年論文

@zh-tw

2017年论文

@wuu

2017年论文

@zh

2017年论文

@zh-cn

name

Switching from originator biol ...... dence and what are the issues?

@en

Switching from originator biol ...... dence and what are the issues?

@nl

type

Item

label

Switching from originator biol ...... dence and what are the issues?

@en

Switching from originator biol ...... dence and what are the issues?

@nl

prefLabel

Switching from originator biol ...... dence and what are the issues?

@en

Switching from originator biol ...... dence and what are the issues?

@nl

P1476

Switching from originator biol ...... dence and what are the issues?

@en

P2093

Eric Toussirot

http://www.w3.org/2001/XMLSchema#string

P2860

Switching to biosimilar infliximab (CT-P13): Evidence of clinical safety, effectiveness and impact on public health

Immunogenicity of biologic agents in rheumatoid arthritis patients: lessons for clinical practice

EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs: 2013 update

Clinical effectiveness of CT-P13 (Infliximab biosimilar) used as a switch from Remicade (infliximab) in patients with established rheumatic disease. Report of clinical experience based on prospective observational data.

Efficacy and safety of switching from reference infliximab to CT-P13 compared with maintenance of CT-P13 in ankylosing spondylitis: 102-week data from the PLANETAS extension study.

Effectiveness of switching between TNF inhibitors in ankylosing spondylitis: data from the NOR-DMARD register.

A randomised, double-blind, parallel-group study to demonstrate equivalence in efficacy and safety of CT-P13 compared with innovator infliximab when coadministered with methotrexate in patients with active rheumatoid arthritis: the PLANETRA study.

A randomised, double-blind, multicentre, parallel-group, prospective study comparing the pharmacokinetics, safety, and efficacy of CT-P13 and innovator infliximab in patients with ankylosing spondylitis: the PLANETAS study

A phase III randomised, double-blind, parallel-group study comparing SB4 with etanercept reference product in patients with active rheumatoid arthritis despite methotrexate therapy.

P304

e000492

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

editorial

P356

10.1136/RMDOPEN-2017-000492

http://www.w3.org/2001/XMLSchema#string

P433

http://www.w3.org/2001/XMLSchema#string

P478

http://www.w3.org/2001/XMLSchema#string

P50

Hubert Marotte

P577

2017-09-12T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

28955498

http://www.w3.org/2001/XMLSchema#string

P932

5604708

http://www.w3.org/2001/XMLSchema#string

Switching from originator biological agents to biosimilars: what is the evidence and what are the issues?

about

P2860

P2860

Switching from originator biological agents to biosimilars: what is the evidence and what are the issues?

description

name

type

label

prefLabel

P1433

P1476

P2093

P2860

P304

P31

P356

P433

P478

P50

P577

P698

P932

P356

P1433

P1476

P2093

P2860

P304

P31

P356

P433

P478

P50

P577

P698

P932